Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01162 ...
Drug Name Terazosin
Molecular Weight 387.4329
Molecular Formula C19H25N5O4
CAS Number 63590-64-7
SMILES COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1
External Links
DRUGBANK DB01162
T3DB T3D3537
PubChem Compound 5401
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 272.5 ℃ 271-274 ℃ [MSDS]

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
Absorption 90.0 % 90 % DRUGBANK
Bioavailability 82.0 % 82.0 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 16.0 ng/ml 16.0 ng/ml Tablet, PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.7 h 1.7 h Tablet, PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 4.8 L/h 80.0 ml/min Plasma clearance; DRUGBANK
Clearance 0.60 L/h 10.0 ml/min Renal clearance; DRUGBANK
Clearance 0.0690 L/h/kg 1.1-1.2 ml/min/kg The Pharmacological Basis of Therapeutics
Clearance 0.0660 L/h/kg 1.1 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 27.5 L 25-30 L DRUGBANK
Volume of Distribution 1.1 L/kg 1.1 L/kg Plasma clearance; hypertension; patients; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.98 L/kg 0.98 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 12.0 h 12 h DRUGBANK
Half-life 14.0 h 14 h Geriatric; DRUGBANK
Half-life 11.4 h 11.4 h adults; DRUGBANK
Half-life 10.5 h 9-12 h The Pharmacological Basis of Therapeutics
Half-life 9.0 h 9 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 5500.0 mg/kg 5500.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 259.3 mg/kg 259.3 mg/kg intravenous injection, IV; parenteral administration; mouse; T3DB
Eliminate Route 40.0 % 40 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 60.0 % 60 % Faeces excretion; PO, oral; DRUGBANK
Eliminate Route 10.0 % ~10 % Urinary excretion; PO, oral; Unchanged drug; DRUGBANK
Eliminate Route 12.5 % 11-14 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 92.0 % 90-94 % DRUGBANK
Protein Binding 92.0 % 90-94 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1